Form 4: United Therapeutics Director Sells Shares Under Pre-Arranged Plan

Nilda Mesa, a Director at United Therapeutics Corp (UTHR), reported the sale of 645 shares of common stock for approximately $289.99 per share under a Rule 10b5-1 plan.

Summary

• Nilda Mesa, a Director of United Therapeutics Corp (UTHR), reported a transaction involving the sale of common stock.
• The transaction occurred on June 24, 2025.
• A total of 645 shares of common stock were disposed of.
• The shares were sold at a weighted average price of $289.9926 per share, with individual trade prices ranging from $289.68 to $290.05.
• Following this transaction, Nilda Mesa beneficially owns 4,883 shares of United Therapeutics common stock.
• The sale was conducted pursuant to a Rule 10b5-1 plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 5

Explanation: Neutral. A Form 4 reports a factual transaction. The sale under a 10b5-1 plan mitigates negative sentiment often associated with insider sales, indicating it was pre-planned rather than reactive to new information.

Positives

• The sale was executed under a Rule 10b5-1 plan, which suggests the transaction was pre-scheduled and not based on new, non-public information, potentially mitigating negative investor perception.

Negatives

• A director selling shares, even under a pre-arranged plan, reduces their direct ownership stake in the company, which some investors might interpret as a lack of increasing confidence.

Future Outlook

The document, an SEC Form 4, reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: The sale by a director could be interpreted differently by shareholders; some might view it as a routine portfolio management action, especially given the Rule 10b5-1 plan, while others might perceive it as a reduction in insider alignment.

Next Steps

• The reporting person undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Dates

Keywords

United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Sale, Director, Nilda Mesa, Rule 10b5-1